Abingdon Health Plc

LSE ABDX.L

Abingdon Health Plc Total Assets for the year ending June 30, 2024: USD 6.44 M

Abingdon Health Plc Total Assets is USD 6.44 M for the year ending June 30, 2024, a -16.26% change year over year. Total assets are the total value of all assets owned by a company, representing its resources.

Abingdon Health Plc Total Assets for the year ending June 30, 2023 was USD 7.69 M, a -50.52% change year over year.
Abingdon Health Plc Total Assets for the year ending June 30, 2022 was USD 15.55 M, a -66.16% change year over year.
Abingdon Health Plc Total Assets for the year ending June 30, 2021 was USD 45.95 M, a 237.85% change year over year.
Abingdon Health Plc Total Assets for the year ending June 30, 2020 was USD 13.60 M, a 46.18% change year over year.

Key data

Date	Total Assets	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity

LSE: ABDX.L

Abingdon Health Plc

CEO	Mr. Chris Henry Francis Yates
IPO Date	Dec. 15, 2020
Location	United Kingdom
Headquarters	York Biotech Campus
Employees	84
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

Abingdon Health Plc develops, manufactures, and distributes diagnostic devices worldwide. It offers AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test; nucleic acid lateral flow immunoassays; Seralite, a rapid lateral flow test for the quantitative measurement of kappa and lambda immunoglobulin free light chains in serum; and AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader. The company also provides lateral flow development and manufacturing services. Additionally, it provides consultancy services to businesses in the healthcare technology sector. The company has a collaboration and co-marketing agreement with Abcam plc. Abingdon Health Plc was incorporated in 2008 and is headquartered in York, the United Kingdom.

Key trends

Past 5 years